Endo Withdraws Opana Painkiller From Market at FDA’s Request

Endo will withdraw Opana ER from the market, following an FDA request in June.

The agency made the request after determining the benefits of the extended-release opioid painkiller no longer outweighed the risks of its abuse.

Postmarket data showed a change in the main route of abuse of Opana ER (oxymorphone hydrochloride) from snorting to intravenous injection, after the pill was reformulated with deterrent properties.